Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to China Asset Insight, a MeritsIP publication examining how emerging life science programs can translate into credible
Introduction: This week, 11 biopharmaceutical companies completed financing, covering AI pharmaceuticals, neuromodulation, in vivo CAR-T, molecular diagnostics, and other sectors. Anlan Dejian has invested nearly 100
Introduction So far, the drug patent linkage system has profoundly changed the competitive landscape of China’s pharmaceutical market—it directly determines when generics can be launched, whether
From scientific potential to “collaborative assets,” the scientific, intellectual property, and cross-border BD evaluation framework for inhaled antifibrotic projects < a set of public information evaluation methods targeting Chinese
· Baoji's Patent Authorization Achievements in the First Half of the Year · Fujian's Longyan: Introduces Guidelines for "Pay-after-Use" Patent Model · Shaanxi Shangnan County Market
In the pharmaceutical field, whether an invention can obtain a patent or remain valid depends not only on the technical quality of the invention itself but
Why is a small molecule of the RAGE pathway, an oral drug with long-term human safety accumulation, worth the attention of Chinese pharmaceutical companies? — Core judgment of
Recently, the biopharmaceutical industry has seen multiple developments: Quan Zhen Tong has released the “Quan Diagnosis 5.0” clinical AI intelligent partner; The approved protection rate of
In biopatent practice, “serial identity” is a frequent pain point during the drafting and examination response stages of claims. Broad identities are prone to scrutiny that
On July 30, the National Intellectual Property Administration issued Decision No. 588094 invalidation request, upholding the validity of the invention patent right for “a pharmaceutical composition and